Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: neurokinin receptor antagonists - GlaxoSmithKline

Drug Profile

Research programme: neurokinin receptor antagonists - GlaxoSmithKline

Alternative Names: SB 235375; SB 733210

Latest Information Update: 06 Jan 2009

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Class Acetic acids; Quinolines; Small molecules
  • Mechanism of Action Neurokinin 2 receptor antagonists; Neurokinin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Respiratory tract disorders

Most Recent Events

  • 22 Jun 2004 Data presented at the 100th International Conference of the American Thoracic Society (ATS-2004) have been added to the Respiratory disorders pharmacodynamics section
  • 23 Apr 2002 Preclinical trials in Respiratory tract disorders in USA (unspecified route)
  • 23 Apr 2002 Preclinical trials in Respiratory tract disorders in Italy (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top